 Finally, because of their impaired ability to degrade anandamide, "FAAH" KOs also display supersensitivity to exogenous anandamide, a cannabinoid receptor (CB) agonist.Due to the ability of FAAH to regulate nociception, it is currently viewed as an attractive drug target for the treatment of pain.A Scottish woman with a previously unreported genetic mutation (dubbed FAAH-OUT) in her FAAH gene with resultant elevated anandamide levels was reported in 2019 to be immune to anxiety, unable to experience fear, and insensitive to pain.